“…These remarkable efficacy data of ECT were mainly found in the predominant indication of therapy-resistant depression and have stimulated ECT to be used successfully in a variety of mental and neurological disorders such as first-episode schizophrenia ( Grover et al, 2019 ), acute mania ( Zhang et al, 2021 ), during the early stages of antidepressive treatment ( Haq et al, 2015 ; van Diermen et al, 2018 ), for motor and behavioral symptoms of Parkinson’s disease ( Takamiya et al, 2021 ), and for sustaining mood improvement in geriatric depression ( Kellner et al, 2016 ). Furthermore, ECT is particularly effective in patients with depression, including psychotic features and elderly people with depression ( van Diermen et al, 2018 ), to be beneficial as an augmenting strategy in treatment-resistant schizophrenia ( Grover et al, 2019 ; Sinclair et al, 2019 ; Chiu et al, 2020 ) with maintenance ECT providing an effective form of relapse prevention ( Ward et al, 2018 ), in mania ( Elias et al, 2021 ), catatonia ( Kellner et al, 2020 ), severe agitation ( Grover et al, 2019 ), specific mental disorders in multiple sclerosis ( Yahya and Khawaja, 2021 ), and prepartum and postpartum psychotic states ( Gazdag et al, 2009 ). Even for children and adolescents, no absolute contra indications for ECT have been seen ( Døssing and Pagsberg, 2021 ).…”